脊柱关节炎中IL-17抑制与亚临床肠道菌群扰动及IL-25驱动的肠道炎症相关
本研究分析PsA/SpA患者接受TNFi或IL-17i治疗前后粪便菌群及细胞因子,发现IL-17i后特定菌群变化(如Clostridiales、Candida albicans),且IL-17i相关克罗恩病回肠活检显示IL-25/IL-17E产生细胞及ILC2扩增。
要点
- IL-17i治疗SpA后出现亚临床肠道菌群扰动,以Clostridiales和Candida albicans变化为著。
- IL-17i相关克罗恩病与IL-25/IL-17E产生簇细胞及ILC2扩增相关。
- 这些发现可能解释IL-17通路抑制与SpA肠道炎症的潜在联系。
核心结论
- 在部分SpA患者中,IL-17A阻断启动与亚临床肠道炎症及特定细菌和真菌(最显著为Candida albicans)菌群失调相关。
- IL-17i相关克罗恩病与IL-25/IL-17E产生簇细胞及ILC2过表达相关。
研究设计与样本
- 研究纳入PsA/SpA患者,接受TNFi(n=15)或抗IL-17A单克隆抗体抑制剂(IL-17i,n=14)治疗前后采集粪便样本。
- 粪便样本进行16S rRNA、内转录间隔区及鸟枪法宏基因组测序和计算菌群分析,并检测脂肪酸代谢物及细胞因子/蛋白水平。
- 另对IL-17i治疗后发生临床明显克罗恩病的SpA患者(n=5)回肠活检进行分析。
主要发现
- 与TNFi相比,IL-17i治疗后特定分类群丰度显著变化,尤其是Clostridiales(P=0.016)和Candida albicans(P=0.041)。
- 这些亚临床变化与细菌群落共现、代谢通路、IL-23/Th17相关细胞因子及多种脂肪酸的变化相关。
- 回肠活检显示,与IL-17i治疗前水平相比,临床明显克罗恩病与IL-25/IL-17E产生簇细胞及ILC2扩增相关(P<0.05)。
关键数值与推荐
- IL-17i后Clostridiales丰度变化P=0.016,Candida albicans丰度变化P=0.041。
- IL-17i相关克罗恩病回肠活检中IL-25/IL-17E产生簇细胞及ILC2扩增P<0.05。
临床怎么用
- 对于接受IL-17i治疗的SpA患者,需关注肠道症状及亚临床肠道炎症可能。
- IL-17i治疗期间出现肠道症状时,应考虑评估克罗恩病可能。
局限性
- 研究样本量有限(TNFi组n=15,IL-17i组n=14,克罗恩病活检n=5)。
- 研究为观察性分析,无法确定因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize the ecological effects of biologic therapies on the gut bacterial and fungal microbiome in psoriatic arthritis (PsA)/spondyloarthritis (SpA) patients. METHODS: Fecal samples from PsA/SpA patients pre- and posttreatment with tumor necrosis factor inhibitors (TNFi; n = 15) or an anti-interleukin-17A monoclonal antibody inhibitor (IL-17i; n = 14) underwent sequencing (16S ribosomal RNA, internal transcribed spacer and shotgun metagenomics) and computational microbiome analysis. Fecal levels of fatty acid metabolites and cytokines/proteins implicated in PsA/SpA pathogenesis or intestinal inflammation were correlated with sequence data. Additionally, ileal biopsies obtained from SpA patients who developed clinically overt Crohn's disease (CD) after treatment with IL-17i (n = 5) were analyzed for expression of IL-23/Th17-related cytokines, IL-25/IL-17E-producing cells, and type 2 innate lymphoid cells (ILC2s). RESULTS: There were significant shifts in abundance of specific taxa after treatment with IL-17i compared to TNFi, particularly Clostridiales (P = 0.016) and Candida albicans (P = 0.041). These subclinical alterations correlated with changes in bacterial community co-occurrence, metabolic pathways, IL-23/Th17-related cytokines, and various fatty acids. Ileal biopsies showed that clinically overt CD was associated with expansion of IL-25/IL-17E-producing tuft cells and ILC2s (P < 0.05), compared to pre-IL-17i treatment levels. CONCLUSION: In a subgroup of SpA patients, the initiation of IL-17A blockade correlated with features of subclinical gut inflammation and intestinal dysbiosis of certain bacterial and fungal taxa, most notably C albicans. Further, IL-17i-related CD was associated with overexpression of IL-25/IL-17E-producing tuft cells and ILC2s. These results may help to explain the potential link between inhibition of a specific IL-17 pathway and the (sub)clinical gut inflammation observed in SpA.
引用
- Manasson J, Wallach DS, Guggino G, et al. Interleukin-17 Inhibition in Spondyloarthritis Is Associated With Subclinical Gut Microbiome Perturbations and a Distinctive Interleukin-25-Driven Intestinal Inflammation. Arthritis Rheumatol. 2020. PMID: 31729183. doi:10.1002/art.41169
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。